Tenax Therapeutics, Inc. (TENX)

NCM – Real vaqt narxi. Valyuta: USD

12.17

+0.22 (1.84%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical operations, medical, product development, and commercial roles.

04.05.2026

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience

22.04.2026

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R.

10.03.2026

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress.

03.03.2026

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL.

04.02.2026

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY.

09.01.2026

Tenax Therapeutics: A Speculative Buy

Tenax Therapeutics is a speculative BUY, driven by the commercial potential of levosimendan for PH-HFpEF and a favorable risk/reward profile. Levosimendan's Phase III trial remains well powered, but the main end-point risk persists, with a realistic 60–70% chance of success. The risk-adjusted conservative revenue estimate for TENX's lead asset well supports the company's current $450M market cap with substantial upside optionality.

Videolar

No Data

There is no data to display

Press-relizlar

08.05.2026

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04.05.2026

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

22.04.2026

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

10.03.2026

Tenax Therapeutics, Inc. (TENX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics: A Speculative Buy

Videolar

No Data

Press-relizlar

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics: A Speculative Buy

Videolar

No Data

Press-relizlar

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Search stocks

Tenax Therapeutics, Inc. (TENX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics: A Speculative Buy

Videolar

No Data

Press-relizlar

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics: A Speculative Buy

Videolar

No Data

Press-relizlar

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update